Zhang Weifeng, Chen Yanru, Lin Chunmei, Peng Weilin, Fu Qingliu, Lin Yiming
Department of Neonatology, Quanzhou Maternity and Children's Hospital, Quanzhou, China.
Center of Neonatal Disease Screening, Quanzhou Maternity and Children's Hospital, Quanzhou, China.
Front Pediatr. 2021 Nov 12;9:771922. doi: 10.3389/fped.2021.771922. eCollection 2021.
Carnitine palmitoyltransferase 1A (CPT1A) deficiency is an inherited disorder of mitochondrial fatty acid β-oxidation that impairs fasting ketogenesis and gluconeogenesis in the liver. Few studies implementing newborn screening (NBS) for CPT1A deficiency in the Chinese population have been reported. This study aimed to determine the biochemical, clinical, and genetic characteristics of patients with CPT1A deficiency in China. A total of 204,777 newborns were screened using tandem mass spectrometry at Quanzhou Maternity and Children's Hospital between January 2017 and December 2018. Newborns with elevated C0 levels were recruited, and suspected patients were subjected to further genetic analysis. Additionally, all Chinese patients genetically diagnosed with CPT1A deficiency were reviewed and included in the study. Among the 204,777 screened newborns, two patients were diagnosed with CPT1A deficiency; thus, the estimated incidence in the selected population was 1:102,388. In addition to the two patients newly diagnosed with CPT1A deficiency, we included in our cohort 10 Chinese patients who were previously diagnosed. Five of these 12 patients were diagnosed NBS. All patients exhibited elevated C0 and/or C0/(C16+C18) ratios. No clinical symptoms were observed in the five patients diagnosed NBS, while all seven patients presented with clinical symptoms, including fever, cough, vomiting, diarrhea, and seizures. Eighteen distinct variants were identified, 15 of which have been previously reported. The three novel variants were c.272T>C (p.L91P), c.734G>A (p.R245Q), and c.1336G>A (p.G446S). analysis suggested that all three novel variants were potentially pathogenic. The most common variant was c.2201T>C (p.F734S), with an allelic frequency of 16.67% (4/24). Our findings demonstrated that NBS for CPT1A deficiency is beneficial. The three novel variants expand the mutational spectrum of in the Chinese population, and c.2201T>C (p.F734S) may be a potential hotspot mutation.
肉碱棕榈酰转移酶1A(CPT1A)缺乏症是一种线粒体脂肪酸β氧化的遗传性疾病,会损害肝脏中的空腹生酮作用和糖异生作用。在中国人群中,实施CPT1A缺乏症新生儿筛查(NBS)的研究报道较少。本研究旨在确定中国CPT1A缺乏症患者的生化、临床和遗传特征。2017年1月至2018年12月期间,泉州市妇幼保健院对204,777名新生儿进行了串联质谱筛查。招募了C0水平升高的新生儿,并对疑似患者进行进一步的基因分析。此外,对所有经基因诊断为CPT1A缺乏症的中国患者进行了回顾并纳入研究。在204,777名接受筛查的新生儿中,有两名患者被诊断为CPT1A缺乏症;因此,所选人群中的估计发病率为1:102,388。除了两名新诊断为CPT1A缺乏症的患者外,我们的队列中还纳入了10名先前诊断的中国患者。这12名患者中有5名是通过NBS诊断的。所有患者的C0和/或C0/(C16+C18)比值均升高。在通过NBS诊断的5名患者中未观察到临床症状,而所有7名患者均出现临床症状,包括发热、咳嗽、呕吐、腹泻和癫痫发作。共鉴定出18种不同的变异,其中15种先前已有报道。三种新变异为c.272T>C(p.L91P)、c.734G>A(p.R245Q)和c.1336G>A(p.G446S)。分析表明,这三种新变异均可能具有致病性。最常见的变异是c.2201T>C(p.F734S),等位基因频率为16.67%(4/24)。我们的研究结果表明,CPT1A缺乏症的NBS是有益的。这三种新变异扩展了中国人群中该疾病的突变谱,c.2201T>C(p.F734S)可能是一个潜在的热点突变。